{"id":3616,"date":"2020-12-03T18:24:29","date_gmt":"2020-12-03T17:24:29","guid":{"rendered":"https:\/\/www.isrec.ch\/recherche\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/"},"modified":"2025-01-27T12:42:25","modified_gmt":"2025-01-27T11:42:25","slug":"immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc","status":"publish","type":"recherche","link":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/","title":{"rendered":"<strong>Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)<\/strong> &#8211; Dr. Sacha Rothschild (University Hospital Basel)"},"content":{"rendered":"<div class=\"intro-text\">\n<p>This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years.<\/p>\n<\/div>\n<p><a href=\"https:\/\/www.isrec.ch\/app\/uploads\/2024\/02\/Rotschild_E_03.12.220.pdf\" target=\"_blank\" rel=\"noopener\">Project<\/a><\/p>\n","protected":false},"featured_media":0,"template":"","cat-recherche":[75],"class_list":["post-3616","recherche","type-recherche","status-publish","hentry","cat-recherche-archive"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.9 - aioseo.com -->\n\t<meta name=\"description\" content=\"This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.9\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Fondation ISREC -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) \u2013 Dr. Sacha Rothschild (University Hospital Basel) - Fondation ISREC\" \/>\n\t\t<meta property=\"og:description\" content=\"This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.isrec.ch\/app\/uploads\/2023\/11\/ISREC_logo_rvb.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.isrec.ch\/app\/uploads\/2023\/11\/ISREC_logo_rvb.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"2362\" \/>\n\t\t<meta property=\"og:image:height\" content=\"1181\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-12-03T17:24:29+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-01-27T11:42:25+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FondationISREC?locale=fr_FR\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@FondationIsrec\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) \u2013 Dr. Sacha Rothschild (University Hospital Basel) - Fondation ISREC\" \/>\n\t\t<meta name=\"twitter:description\" content=\"This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.isrec.ch\/app\/uploads\/2023\/11\/ISREC_logo_rvb.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/research\\\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/cat-recherche\\\/archive\\\/#listItem\",\"name\":\"Archive\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/cat-recherche\\\/archive\\\/#listItem\",\"position\":2,\"name\":\"Archive\",\"item\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/cat-recherche\\\/archive\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/research\\\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\\\/#listItem\",\"name\":\"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) &#8211; Dr. Sacha Rothschild (University Hospital Basel)\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/research\\\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\\\/#listItem\",\"position\":3,\"name\":\"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) &#8211; Dr. Sacha Rothschild (University Hospital Basel)\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/cat-recherche\\\/archive\\\/#listItem\",\"name\":\"Archive\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/#organization\",\"name\":\"Fondation ISREC\",\"url\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/\",\"sameAs\":[\"https:\\\/\\\/twitter.com\\\/FondationIsrec\",\"https:\\\/\\\/www.instagram.com\\\/fondation_isrec_lausanne\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@fondationisrec8946\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/fondation-isrec\\\/\"]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/research\\\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\\\/#webpage\",\"url\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/research\\\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\\\/\",\"name\":\"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) \\u2013 Dr. Sacha Rothschild (University Hospital Basel) - Fondation ISREC\",\"description\":\"This \\u201callocated fund in clinical research\\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/research\\\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\\\/#breadcrumblist\"},\"datePublished\":\"2020-12-03T18:24:29+01:00\",\"dateModified\":\"2025-01-27T12:42:25+01:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/\",\"name\":\"Fondation ISREC\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.isrec.ch\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) \u2013 Dr. Sacha Rothschild (University Hospital Basel) - Fondation ISREC","description":"This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project","canonical_url":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.isrec.ch\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/www.isrec.ch\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.isrec.ch\/en\/cat-recherche\/archive\/#listItem","name":"Archive"}},{"@type":"ListItem","@id":"https:\/\/www.isrec.ch\/en\/cat-recherche\/archive\/#listItem","position":2,"name":"Archive","item":"https:\/\/www.isrec.ch\/en\/cat-recherche\/archive\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/#listItem","name":"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) &#8211; Dr. Sacha Rothschild (University Hospital Basel)"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.isrec.ch\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/#listItem","position":3,"name":"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) &#8211; Dr. Sacha Rothschild (University Hospital Basel)","previousItem":{"@type":"ListItem","@id":"https:\/\/www.isrec.ch\/en\/cat-recherche\/archive\/#listItem","name":"Archive"}}]},{"@type":"Organization","@id":"https:\/\/www.isrec.ch\/en\/#organization","name":"Fondation ISREC","url":"https:\/\/www.isrec.ch\/en\/","sameAs":["https:\/\/twitter.com\/FondationIsrec","https:\/\/www.instagram.com\/fondation_isrec_lausanne\/","https:\/\/www.youtube.com\/@fondationisrec8946","https:\/\/www.linkedin.com\/company\/fondation-isrec\/"]},{"@type":"WebPage","@id":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/#webpage","url":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/","name":"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) \u2013 Dr. Sacha Rothschild (University Hospital Basel) - Fondation ISREC","description":"This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/www.isrec.ch\/en\/#website"},"breadcrumb":{"@id":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/#breadcrumblist"},"datePublished":"2020-12-03T18:24:29+01:00","dateModified":"2025-01-27T12:42:25+01:00"},{"@type":"WebSite","@id":"https:\/\/www.isrec.ch\/en\/#website","url":"https:\/\/www.isrec.ch\/en\/","name":"Fondation ISREC","inLanguage":"en-US","publisher":{"@id":"https:\/\/www.isrec.ch\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Fondation ISREC -","og:type":"article","og:title":"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) \u2013 Dr. Sacha Rothschild (University Hospital Basel) - Fondation ISREC","og:description":"This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project","og:url":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/","og:image":"https:\/\/www.isrec.ch\/app\/uploads\/2023\/11\/ISREC_logo_rvb.jpg","og:image:secure_url":"https:\/\/www.isrec.ch\/app\/uploads\/2023\/11\/ISREC_logo_rvb.jpg","og:image:width":2362,"og:image:height":1181,"article:published_time":"2020-12-03T17:24:29+00:00","article:modified_time":"2025-01-27T11:42:25+00:00","article:publisher":"https:\/\/www.facebook.com\/FondationISREC?locale=fr_FR","twitter:card":"summary","twitter:site":"@FondationIsrec","twitter:title":"Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC) \u2013 Dr. Sacha Rothschild (University Hospital Basel) - Fondation ISREC","twitter:description":"This \u201callocated fund in clinical research\u201d was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years. Project","twitter:image":"https:\/\/www.isrec.ch\/app\/uploads\/2023\/11\/ISREC_logo_rvb.jpg"},"aioseo_meta_data":{"post_id":"3616","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-10-20 09:12:00","updated":"2025-07-30 22:23:16","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.isrec.ch\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.isrec.ch\/en\/cat-recherche\/archive\/\" title=\"Archive\">Archive<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<strong>Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)<\/strong> \u2013 Dr. Sacha Rothschild (University Hospital Basel)\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.isrec.ch\/en\/"},{"label":"Archive","link":"https:\/\/www.isrec.ch\/en\/cat-recherche\/archive\/"},{"label":"<strong>Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)<\/strong> &#8211; Dr. Sacha Rothschild (University Hospital Basel)","link":"https:\/\/www.isrec.ch\/en\/research\/immune-modulatory-radiotherapy-to-enhance-the-effects-of-neo-adjuvant-pd-l1-blockade-after-neo-adjuvant-chemotherapy-in-patients-with-resectable-stage-iii-n2-non-small-cell-lung-cancer-nsclc\/"}],"_links":{"self":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/recherche\/3616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/recherche"}],"about":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/types\/recherche"}],"wp:attachment":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/media?parent=3616"}],"wp:term":[{"taxonomy":"cat-recherche","embeddable":true,"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/cat-recherche?post=3616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}